PRNewsWire
03 Aug 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA granted Breakthrough Therapy designation to Eli Lilly's olomorasib for the treatment of KRAS G12C-mutant advanced pancreatic cancer. — Breakthrough designation accelerates the regulatory path for a drug targeting a high-unmet-need area with no current approved therapies.
+0.60Olomorasib has now received two Breakthrough Therapy designations, covering both pancreatic and non-small cell lung cancers (NSCLC). — Expanding the potential indications for the drug increases the total addressable market and validates the platform's broad clinical potential.
+0.40The FDA designation is based on preliminary results from the Phase 1/2 LOXO-RAS-20001 study. — Confirmation that clinical data is supporting the regulatory progress, though still in early-stage trials.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
